115371 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21248)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66748)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3742)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21248)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115371)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Very low dose radiation therapy for indolent lymphoma: Comparing "Big Boom" (4GY × 1) versus "Boom Boom" (2GY × 2)
    Meeting Abstract

    Hajj, C.; Lee, J.; Boe, L.; Fregonese, B.; Lebow, E.; Wijetunga, N. A.; Hubbeling, H.; Tringale, K.; Freret, M.; Imber, B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • AFM13 in patients with CD30 positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL): Results from the phase 2 redirect study
    Meeting Abstract

    Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhaylova, N.; Marin‐Niebla, A.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • BRCA1/2 mutations impact on the development of breast implant‐associated lymphoma (BIA‐ALCL) in women with breast cancer reconstructed with textured breast implants
    Meeting Abstract

    Ghione, P.; Arcila, M.; Joseph, V.; Dogan, A.; Cordeiro, P.; Salles, G.; de Jong, D.; Horwitz, S.; Mandelker, D.; van Leeuwen, F.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • High complete metabolic response rates with epcoritamab + R‐CHOP in previously untreated (1L) high‐risk DLBCL, including double‐hit/triple‐hit: EPCORE NHL‐2 update
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Chromatin accessibility profiling to increase diagnostic accuracy and refine cell‐of‐origin classification of mature T‐cell lymphomas
    Meeting Abstract

    Julia, E.; Mareschal, S.; Chebel, A.; Camille, G.; Missaglia, E.; Rattina, V.; Lours, C.; Testard, Q.; Tschantz, M.; Sebai, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Circulating tumor DNA (CTDNA) status and clinical outcomes in patients (PTS) with previously untreated diffuse large B‐cell lymphoma (DLBCL) in the POLARIX study
    Meeting Abstract

    Herrera, A. F.; Tracy, S.; Sehn, L. H.; Jardin, F.; Lenz, G.; Trněný, M.; Salles, G.; Flowers, C. R.; Tilly, H.; Sharman, J. P.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL): Extended follow‐up and landmark analyses from a pivotal phase II study
    Meeting Abstract

    Dickinson, M.; Carlo‐Stella, C.; Morschhauser, F.; Falchi, L.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez‐Lopez, J.; Bartlett, N.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save